Finance

Lists
Q3 2026 earnings • released • EPS miss -84.80% • Revenue miss -17.53%
See results
IBRX:NASDAQ
Immunitybio Inc
$6.07
-9.00%
(-0.60) 1D
$6.10
+0.49% (+0.030)
Pre-market
Closed: Nov 12, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IBRX...
Open
$6.45
High
$6.50
Low
$6.00
Mkt. cap
6.46B
Avg. vol.
14.84M
Volume
501.00
52-wk high
$12.43
52-wk low
$1.95
EPS
-$1.07
Beta
0.17
Shares outstanding
1.06B
No. of employees
688
Open
$6.45
High
$6.50
Low
$6.00
Mkt. cap
6.46B
Avg. vol.
14.84M
Volume
501.00
52-wk high
$12.43
52-wk low
$1.95
EPS
-$1.07
Beta
0.17
Shares outstanding
1.06B
No. of employees
688
News stories
From web sources and news partners
About Immunitybio Inc
CEORich Adcock
Employees688
Founded2014
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteimmunitybio.com
Analyst ratings
Based on 4 analysts giving stock ratings to IBRX in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for IBRX in the last 3 months.
Highest
Current $6.07
$16.00 (+163.59%)
Average
$14.25 (+134.76%)
Lowest
$12.00 (+97.69%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jeet Mukherjee
BTIG
Buy
Maintained
$12.00
+97.7%
11/09/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
$15.00
+147.1%
11/09/2026
Kelly Shi
Jefferies
Buy
Maintained
$14.00
+130.6%
10/14/2026
Edward Tenthoff
Piper Sandler
Buy
Maintained
$16.00
+163.6%
10/14/2026
Last report
Nov 9, 2026
Fiscal period
Q3 2026
-$0.09 / -$0.05
-84.80%miss
Revenue / Est. (USD)
48.84M / 59.22M
-17.53%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
38.28M
44.21M
51.24M
48.84M
Cost of goods sold
382.00K
238.00K
298.00K
1.29M
Cost of revenue
382.00K
238.00K
298.00K
1.29M
Research and development expenses
67.26M
67.99M
60.82M
71.34M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35.33M
45.77M
51.82M
54.20M
Operating expense
102.59M
113.76M
112.64M
125.54M
Total operating expenses
102.97M
114.00M
112.94M
126.83M
Operating income
-64.68M
-69.79M
-61.70M
-77.99M
Other non operating income
27.48M
-529.45M
-140.60M
-77.74M
EBT including unusual items
-62.09M
-632.79M
-230.39M
-184.56M
EBT excluding unusual items
-62.09M
-625.39M
-230.39M
-184.56M
Income tax expense
-135.00K
9.00K
-
-
Effective tax rate
0.22%
-
-
-
Other operating expenses
-
-
-
-
Net income
-61.94M
-632.78M
-230.38M
-184.55M
Net profit margin
-161.80%
-1,431.44%
-449.61%
-377.86%
Earnings per share
-0.06
-0.08
-0.22
-0.09
Interest and investment income
2.30M
2.31M
3.16M
3.17M
Interest expense
-27.19M
-28.46M
-31.24M
-32.02M
Net interest expenses
-24.89M
-26.15M
-28.09M
-28.84M
Depreciation and amortization charges
-
-
-
-
EBITDA
-60.92M
-65.41M
-57.29M
-74.10M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps